nabilone Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 1862 | 51022-71-0 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
cannabinol deriv; RN given refers to cpd without isomeric designation; structure
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 3 | mg | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BA (Bioavailability) | 20 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Dec. 26, 1985 | FDA | MEDA PHARMS |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| White blood cell count abnormal | 289.11 | 25.80 | 67 | 2978 | 5065 | 46677952 |
| Somatic symptom disorder | 140.27 | 25.80 | 31 | 3014 | 1881 | 46681136 |
| Sacroiliitis | 136.38 | 25.80 | 31 | 3014 | 2138 | 46680879 |
| Gait disturbance | 134.69 | 25.80 | 95 | 2950 | 145168 | 46537849 |
| Musculoskeletal stiffness | 134.59 | 25.80 | 82 | 2963 | 97911 | 46585106 |
| Rheumatoid arthritis | 92.93 | 25.80 | 95 | 2950 | 240120 | 46442897 |
| Insomnia | 92.07 | 25.80 | 80 | 2965 | 164844 | 46518173 |
| Mood altered | 85.17 | 25.80 | 32 | 3013 | 12975 | 46670042 |
| Therapeutic product effect incomplete | 71.90 | 25.80 | 51 | 2994 | 78102 | 46604915 |
| Drug hypersensitivity | 67.47 | 25.80 | 81 | 2964 | 243744 | 46439273 |
| Pain | 66.31 | 25.80 | 114 | 2931 | 476834 | 46206183 |
| Cognitive disorder | 58.62 | 25.80 | 34 | 3011 | 36849 | 46646168 |
| Therapeutic response shortened | 57.89 | 25.80 | 19 | 3026 | 5180 | 46677837 |
| Fibromyalgia | 53.70 | 25.80 | 32 | 3013 | 36431 | 46646586 |
| Occult blood | 51.66 | 25.80 | 12 | 3033 | 908 | 46682109 |
| Acute psychosis | 42.46 | 25.80 | 12 | 3033 | 1980 | 46681037 |
| Dystonia | 34.08 | 25.80 | 16 | 3029 | 11241 | 46671776 |
| Iron deficiency | 30.27 | 25.80 | 12 | 3033 | 5601 | 46677416 |
| Psychotic disorder | 28.55 | 25.80 | 18 | 3027 | 22603 | 46660414 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Pelvic pain | 45.75 | 38.84 | 11 | 889 | 2118 | 29949460 |
| Immune-mediated hepatitis | 41.41 | 38.84 | 9 | 891 | 1107 | 29950471 |
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A04AD11 | ALIMENTARY TRACT AND METABOLISM ANTIEMETICS AND ANTINAUSEANTS ANTIEMETICS AND ANTINAUSEANTS Other antiemetics |
| FDA CS | M0003267 | Cannabinoids |
| FDA EPC | N0000175782 | Cannabinoid |
| MeSH PA | D014151 | Anti-Anxiety Agents |
| MeSH PA | D000932 | Antiemetics |
| MeSH PA | D002491 | Central Nervous System Agents |
| MeSH PA | D002492 | Central Nervous System Depressants |
| MeSH PA | D005765 | Gastrointestinal Agents |
| MeSH PA | D018373 | Peripheral Nervous System Agents |
| MeSH PA | D011619 | Psychotropic Drugs |
| MeSH PA | D014149 | Tranquilizing Agents |
Drug Use (View source of the data)
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Chemotherapy-induced nausea and vomiting | indication | 236084000 | |
| Depressive disorder | contraindication | 35489007 | |
| Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
| Conduction disorder of the heart | contraindication | 44808001 | |
| Low blood pressure | contraindication | 45007003 | |
| Chronic heart failure | contraindication | 48447003 | |
| Schizophrenia | contraindication | 58214004 | DOID:5419 |
| Hepatic failure | contraindication | 59927004 | |
| Substance abuse | contraindication | 66214007 | |
| Psychotic disorder | contraindication | 69322001 | |
| Mania | contraindication | 231494001 | |
| Breastfeeding (mother) | contraindication | 413712001 | |
| Disorder of coronary artery | contraindication | 414024009 |
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 8.7 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Cannabinoid receptor 1 | GPCR | AGONIST | Ki | 8.40 | CHEMBL | CHEMBL | |||
| Cannabinoid receptor 2 | GPCR | Ki | 8.20 | CHEMBL | |||||
| Cannabinoid receptor 1 | GPCR | Ki | 8.66 | CHEMBL | |||||
| Cannabinoid receptor 2 | GPCR | Ki | 8.74 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4019352 | VUID |
| N0000147524 | NUI |
| D05099 | KEGG_DRUG |
| 4019352 | VANDF |
| C1263104 | UMLSCUI |
| CHEBI:135574 | CHEBI |
| CHEMBL2218896 | ChEMBL_ID |
| CHEMBL947 | ChEMBL_ID |
| DB00486 | DRUGBANK_ID |
| C011941 | MESH_SUPPLEMENTAL_RECORD_UI |
| 5284592 | PUBCHEM_CID |
| 9071 | IUPHAR_LIGAND_ID |
| 3930 | INN_ID |
| 2N4O9L084N | UNII |
| 31447 | RXNORM |
| 15778 | MMSL |
| 38357 | MMSL |
| 52672 | MMSL |
| d04587 | MMSL |
| 001686 | NDDF |
| 322124005 | SNOMEDCT_US |
| 395806009 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Cesamet | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0187-1231 | CAPSULE | 1 mg | ORAL | NDA | 22 sections |